



(51) International Patent Classification:

C07D 403/12 (2006.01) *A61K 31/506* (2006.01)
A61K 31/4155 (2006.01) *C07D 491/10* (2006.01)

(21) International Application Number:

PCT/GB2012/052445

(22) International Filing Date:

3 October 2012 (03.10.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

11183682.1	3 October 2011 (03.10.2011)	EP
11183688.8	3 October 2011 (03.10.2011)	EP
12168396.5	16 May 2012 (16.05.2012)	EP
12168395.7	16 May 2012 (16.05.2012)	EP

(71) **Applicant:** RESPIVERT LIMITED [GB/GB]; 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG (GB).

(72) **Inventors:** ITO, Kazuhiro; c/o Respivert Limited, Imperial College BioIncubator, Level 1, Bessemer Building, Imperial College London SW7 2AZ (GB). CHARRON, Catherine Elisabeth; c/o Respivert Limited, Imperial College BioIncubator, Level 1, Bessemer Building, Imperial College London SW7 2AZ (GB). KING-UNDERWOOD, John; Moored Cottage, School Lane, Pendock, Worcestershire, GL19 3PW (GB). ONIONS, Stuart Thomas; c/o Sygnature Chemical Services Ltd, Biocity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF (GB). LONGSHAW, Alistair Ian; c/o Sygnature Chemical Services Ltd, Biocity Nottingham, Pennyfoot Street, Nottingham, Nottinghamshire NG1 1GF (GB). BROECKX, Rudy; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). FILLIERS,

Walter; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). COPMANS, Alex; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE).

(74) **Agents:** TEUTEN, Andrew et al.; Sagittarius IP, Three Globeside, Fieldhouse Lane, Marlow, Buckinghamshire SL7 1HZ (GB).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) **Title:** 1-PYRAZOLYL-3- (4- ((2 -ANILINOPYRIMIDIN- 4 - YL) OXY) NAPHTHALEN- 1 - YL) UREAS AS P38 MAP KINASE INHIBITORS



(57) **Abstract:** There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.